12:00 AM
 | 
Jan 24, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trileptal oxcarbazepine tablets regulatory update

The FDA granted marketing approval for NOVN's Trileptal, an anticonvulsant...

Read the full 28 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >